Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

64.41
-0.2200-0.34%
Pre-market: 63.89-0.5168-0.80%04:22 EDT
Volume:1.95M
Turnover:125.96M
Market Cap:12.45B
PE:169.95
High:65.33
Open:63.83
Low:63.64
Close:64.63
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:1.02
T/O Rate:1.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:1.97
PE(LYR):35.78

Loading ...

BioMarin to receive 20% royalty on net sales of Yuviwel from Ascendis Pharma

TIPRANKS
·
Aug 31

Biomarin Pharmaceutical Shares up 5.6% Premarket After Co Announces Global Settlement with Ascendis Pharma

THOMSON REUTERS
·
Aug 31

BioMarin Settles Patent Lawsuits With Ascendis Pharma Over Yuviwel

MT Newswires Live
·
Aug 31

Biomarin Pharmaceutical - Settlement Includes License for Biomarin Patents Relating to Yuviwel for All Indications

THOMSON REUTERS
·
Aug 31

Biomarin Pharmaceutical - Ascendis to Pay Biomarin 20% Royalty on Yuviwel U.S. Sales, 18% in EU, Brazil, South Korea Until May 2030

THOMSON REUTERS
·
Aug 31

Biomarin Pharmaceutical - to Dismiss Itc Investigation; All Ip Claims Resolved Including Litigation in Multiple Countries

THOMSON REUTERS
·
Aug 31

BioMarin (BMRN) Stock Looks To Trade At A Discount To Fair Value

Simply Wall St.
·
Aug 31

U.S. Stocks on the MOVE-BioMarin Pharmaceutical, Home Depot, Klarna Group

Reuters
·
Aug 18

BioMarin Pharmaceutical's Alesta Deal Strengthens Long-Term Growth Outlook, Wedbush Says

MT Newswires Live
·
Aug 18

Biomarin Pharmaceutical Inc. : H.c. Wainwright Cuts Target Price to $59 from $60

THOMSON REUTERS
·
Aug 18

BioMarin Adds Potential Bone-Disease Treatment to Portfolio

Dow Jones
·
Aug 18

BioMarin Agrees to Buy Alesta Therapeutics for USD 275 Million Upfront

Reuters
·
Aug 18

Biomarin to Acquire Alesta Therapeutics to Gain Ale1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to Biomarin's Pipeline

THOMSON REUTERS
·
Aug 18

Biomarin Pharmaceutical - Deal Expected to be Modestly Dilutive to 2026 Financial Results

THOMSON REUTERS
·
Aug 18

Biomarin Pharmaceutical - Alesta Shareholders Eligible for up to $215 Mln in Milestone Payments

THOMSON REUTERS
·
Aug 18

Biomarin Pharmaceutical - Alesta to Spin Out Non-Ale1 Assets and Employees Before Close

THOMSON REUTERS
·
Aug 18

Biomarin Pharmaceutical - to Fund Acquisition with Cash on Hand

THOMSON REUTERS
·
Aug 18

BioMarin Pharmaceutical is Maintained at Overweight by Piper Sandler

Dow Jones
·
Aug 18

BioMarin price target raised to $88 from $82 at Piper Sandler

TIPRANKS
·
Aug 17

Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Aug 17